Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, represents a new milestone in the treatment of type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.